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Abstract: 
The Strategic Advisory Group of Experts on Immunization (SAGE) advises WHO on global 
policies for vaccines. In April 2016, SAGE issued recommendations on the use of the first 
licensed dengue vaccine, CYD-TDV (Dengvaxia®). In November 2017, data from a 
retrospective analysis of clinical trial data, stratifying participants according to their dengue 
serostatus before the first vaccine dose, revealed that, although in high seroprevalence settings 
the vaccine provides overall population benefit, there was an excess risk of severe dengue in 
seronegative vaccine recipients. The SAGE working group on dengue vaccines was re-
convened to consider the new data. In their deliberations, two vaccination strategies were 
mainly considered.  The first was to use the vaccine only in populations with high dengue 
seroprevalence rates, above 80%, and the second was to screen individuals prior to 
vaccination and to vaccinate only those with serological evidence of previous dengue 
infection. Issues considered included: the feasibility of population seroprevalence studies and 
of individual pre-vaccination serological screening; the numbers of people who would be 
eligible for vaccination under these scenarios; possible effects on public confidence in 
vaccination programmes; ethical concerns; and communication challenges.  Here we report 
on these deliberations that informed the revised SAGE recommendations in April 2018, that 
for countries considering CYD-TDV vaccination as part of their dengue control programme, a 
pre-vaccination screening strategy was preferred, such that only dengue-seropositive persons 
should be vaccinated. SAGE highlighted that important research and implementation 
questions remain for CYD-TDV, including the development of a highly sensitive and specific 
rapid diagnostic test to determine dengue-seropositivity, simplified immunization schedules, 
and assessment of the need for booster doses. 
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A mandate of the World Health Organization (WHO) is to issue guidance on the use of 
vaccines against diseases of public health concern. Once a vaccine has been licensed by a 
functional national regulatory authority (NRA), WHO provides a policy position on the use of 
the product in public health programmes. The Strategic Advisory Group of Experts on 
Immunization (SAGE) advises WHO on global policies and strategies for vaccines and 
immunization, ranging from research and development to delivery of vaccines and their 
linkages with other health interventions. SAGE working groups (WGs), composed of 
independent subject matter experts with geographic diversity, propose recommendations for 
consideration by SAGE with respect to specific vaccines or related issues, using the GRADE 
process to assess the quality of evidence and the DECIDE framework to document the 
evidence-based process of developing recommendations.1 These were used to develop SAGE 
recommendations for the world`s first licensed dengue vaccine, CYD-TDV (Dengvaxia®), 
developed by Sanofi Pasteur. Following the licensure of CYD-TDV in December 2015, in 
April 2016, SAGE made recommendations to WHO on the use of this vaccine2, which led to 
the WHO position paper in July 2016.3 In November 2017, Sanofi Pasteur released new long-
term safety data following additional analyses; the findings revealed an excess risk of severe 
dengue in the vaccinated seronegative trial sub-population.4 The SAGE WG on dengue 
vaccines was re-convened in December 20175 to review the previous SAGE 
recommendations in light of the new evidence of these serious adverse effects. Here we report 
on the deliberations of the SAGE WG between December 2017 and April 2018 that were 
reviewed by SAGE in April 2018 and led to the revised recommendations.6  
 
Background: 
Dengue is the most rapidly spreading mosquito-borne virus disease with wide geographic 
distribution7,8, also increasingly affecting travellers.9,10,11 Effective scalable and sustainable 
vector control measures remain elusive12, and compliance with personal protective measures 
is difficult.13 Hence additional control measures are urgently needed. CYD-TDV is a live 
attenuated tetravalent dengue vaccine, now licensed on a 3-dose schedule in 20 countries in 
Asia, Latin America and Australia, typically for use in persons aged 9-45 years.14 The first 
public vaccination programme with CYD-TDV was launched in the Philippines in April 2016 
with the aim to vaccinate almost 1 million school children in four highly dengue-endemic 
regions.14 The first public dengue vaccination programme in the Americas was also launched 
in 2016 in dengue-endemic parts of Paraná State in Brazil,  deploying about 500,000 vaccine 
doses. In addition, people living in Brazil, Mexico, El Salvador, the Philippines, Costa Rica, 
Indonesia, Peru, Paraguay, Guatemala, Thailand and Singapore can access CYD-TDV 
through the private market. In the other countries, the vaccine has been licensed, but not yet 
been launched (Argentina, Australia, Bolivia, Cambodia, Honduras, Malaysia, Myanmar, 
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Venezuela).14  
Licensure of the vaccine followed the results from two large placebo-controlled Phase 3 trials 
involving over 30,000 participants aged 2 to 16 years in ten highly dengue endemic countries 
in Asia and Latin America15,16 and from a Phase 2b trial in Thailand.17 Post-hoc analyses, 
pooled across the trials, indicated that vaccine efficacy (VE) against symptomatic 
virologically confirmed dengue (VCD), over the 25-month period from the first dose, was 
higher in those aged 9-16 years at first vaccination (VE = 65.6%, 95% CI, 60.7 to 69.9) than 
in those aged 2-8 years (VE = 44.6%, 95% CI, 31.6 to 55.0).18   In the older age group, over 
the same follow-up period, vaccination reduced severe dengue by 93.2% (95% CI, 77.3 to 
98.0) and dengue hospitalizations by 80.8% (95% CI, 70.1 to 87.7).18  
At the time of licensure, an increased risk of hospitalized and severe dengue was noted in the 
third year after first vaccination among those aged 2-5 years. This safety signal was not 
observed in those vaccinated at age 6 years and above. Because of the safety signal in those 
aged 2-5 years, which was not apparent in other age groups, the company sought licensure for 
the age group of 9 years and above. It was unknown whether the safety signal in the 2-5 year 
age group, but not the older children, might be attributable to younger age per se or to the 
higher prevalence of participants who were dengue-naïve (dengue seronegative) in this age 
group, or a combination of both. Pre-vaccination serum samples, to determine baseline 
dengue serostatus, were obtained from only a sample of trial participants (approximately 4000 
children). In this subset, cumulatively over the available observation time of about 4 years, no 
increased risk of hospitalized dengue was seen among seronegative children aged 9-16 years 
(1.8% in the vaccine group versus 2.0% in the control group), whereas in seronegative 
children aged 2-8 years the corresponding rates were 5.2% in the vaccine group and 2.9% in 
the control group.19  From year 3 onwards, in those trial participants aged <9 years, 4.6% of 
the vaccinated and 1.8% of the controls had hospitalizations due to dengue, whilst in those 
aged ≥9 years, there was little difference: 1.9% of those vaccinated and 1.5% control had 
hospitalizations due to dengue. While the small numbers in the immune subset were 
insufficient to address conclusively the role of dengue serostatus at vaccination for those 
older than 9 years, they suggested differential vaccine effects by age. 
 
SAGE recommendations in April 2016: 
During 2015 to 2016, WHO convened 8 modelling groups to model the effects of the vaccine 
in various transmission settings based on data then available. All models assumed that the 
main determinant of the safety signal in 2-5 year olds was serostatus.20,21 It was also assumed 
that the vaccine acts like an asymptomatic dengue infection, without an associated risk of 
disease. In dengue-seronegative individuals, a first infection with a wild-type dengue virus 
following vaccination would behave as a “secondary-like” infection, which would be 
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associated with an increased risk of severe dengue, as seen in natural secondary infections, 
whereas in seropositive individuals a subsequent natural infection following vaccination 
would act as a tertiary-like infection, which is associated with a low risk of severe disease 
naturally.22,23 In high transmission settings, seronegative individuals would experience 
multiple natural infections, such that even if CYD-TDV did prime those seronegative for a 
“secondary-like” infection associated with more severe disease, unvaccinated seronegative 
individuals would very likely experience a second natural infection, with associated increased 
risk of severe dengue. Consequently, the temporary increased risk in seronegative vaccinees 
would be compensated by a reduced risk of severe dengue at later time periods when 
compared to unvaccinated seronegative individuals. Thus, in the longer term, in high 
transmission settings, there would be no net increase in severe dengue in seronegative 
vaccinees.21 For a specific level of transmission, there is an optimal age of vaccination that 
decreases as transmission intensity increases.24 The modelling results suggested that the 
public health benefits of vaccination would be greatest if dengue seropositivity in the age 
group targeted for vaccination was high, i.e. in high seroprevalence settings, 70% by the age 
of 9 years.20,21  
 
SAGE`s 2016 recommendations, which limited the use of the vaccine to high seroprevalence 
settings, balanced the substantial overall reduction in severe dengue through vaccination in 
such settings against the theoretical enhanced risk of severe disease in a subset of those 
vaccinated, which was not apparent in the empiric safety data at that time for the age group 
for which the vaccine was licensed.25 the subsequent WHO position on the use of CYD-TDV 
in July 2016 was formulated as: “Countries should consider introduction of the dengue 
vaccine CYD-TDV only in geographic settings where epidemiological data indicate a high 
burden of disease.  Seroprevalence should be approximately 70% or greater in order to 
maximize public health impact and the vaccine is not recommended when seroprevalence is 
below 50% in the age group targeted for vaccination.”26  
 
When a vaccine is licensed, it is expected that some questions about vaccine safety and 
efficacy, particularly for subpopulations, and rare adverse events as well as duration of 
protection, remain. Hence, the critical need for post-licensure studies. Regulatory authorities 
require manufacturers to conduct such studies under a risk management plan, and countries 
introducing new vaccines are advised to carefully monitor vaccine performance. WHO’s 
guidance to regulatory authorities, stating that long-term safety assessment should be 
monitored post-licensure, follows this rationale and practice.27 Although no safety signal was 
evident by April 2016 in the licensed age group of 9 years and above, SAGE noted the limited 
safety data in seronegative individuals in that age group.2 As the sample from the vaccine 
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trials was of insufficient size to conclusively address the role of pre-vaccination serostatus for 
those aged 9 years or older, WHO stressed the importance of obtaining more data on safety in 
seronegative vaccinees. It was not expected that this issue could be addressed with data from 
the Phase 3 trials because blood samples had not been taken from all trial participants prior to 
vaccination. It was anticipated that long-term prospective studies would be required, of 
individuals who were seronegative at the time of vaccination, to address the possibility of 
enhanced risk in seronegative vaccinees, and WHO hosted a consultation on how such studies 
could be done.28 
 
Long-term safety data stratified by baseline serostatus 
In November 2017, Sanofi Pasteur announced the results of new analyses to assess the 
benefit-risk of vaccination in seronegative individuals. These analyses were made possible 
through the application of a newly developed serological assay, the NS1 IgG ELISA assay29, 
which the company applied to blood samples taken from all trial participants one month after 
the third vaccine dose and which enabled dengue serostatus prior to receiving the first 
vaccination to be inferred retrospectively. As CYD-TDV encodes yellow fever vaccine non-
structural proteins, including NS1, not found after natural dengue infection, the NS1 antibody 
ELISA was able to distinguish previous dengue exposure from non-exposure before 
vaccination with CYD-TDV, with sensitivity estimated to be 95.3% and specificity 68.6%.30 
Using these results, imputation methods were employed to infer baseline serostatus. 
 
The new analyses indicated that, overall, the risk of dengue and severe dengue was 
substantially reduced in those vaccinated, but also highlighted that the vaccine performed 
differently depending on pre-vaccination serostatus.30 In brief, VE against virologically 
confirmed symptomatic dengue in the two years following the first vaccine dose among 
inferred baseline seropositive participants ≥9 years of age was 76% (95% CI: 63.9, to 84.0), 
but only 38.8% (95% CI: –0.9 to 62.9%) among inferred baseline seronegative participants. 
The long-term follow-up, to 60 months, showed that while the vaccine remained efficacious 
and safe in seropositive vaccinees, there was an increased risk of severe dengue in 
seronegative vaccinees from year 3 onwards after the first dose. Among seronegative 
participants aged 9 to 16 years, the cumulative incidence of severe dengue over 5 years was 
0.40% among vaccine recipients and 0.17% among controls, a hazard ratio of 2.44 (95% CI: 
0.47 to 12.56).30 The risk and clinical manifestations of severe dengue in vaccinated 
seronegative individuals aged 9-16 years were similar to those in unvaccinated seropositive 
individuals, consistent with the above-mentioned hypothesis that the vaccine acts as an 
asymptomatic infection. In contrast, there was sustained protection against severe disease in 
seropositive vaccine recipients throughout the 60 months. The hazard ratio of severe dengue 
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was 0.16 (95% CI: 0.07-0.37) in seropositive vaccinated compared to seropositive 
unvaccinated trial participants throughout the 5 years.30 
 
Revised SAGE recommendations April 2018 
During the SAGE deliberations in 2016, the possibility of an increased risk of severe dengue 
in a subset of those in the age group for which the vaccine was licensed was a theoretical 
possibility, but such a risk was not apparent in the clinical trial data available at the time. The 
new analyses identified an increased risk of severe dengue in seronegative individuals in the 
age range for which the vaccine was licenced, which necessitated revision of the 2016 SAGE 
recommendations. The SAGE WG on dengue vaccines was reconvened in December 2017, to 
reconsider the benefit-risk assessment for the public health use of CYD-TDV in light of the 
new data.5 Based on the new results from the trials, in a vaccinated group with 70% dengue 
seroprevalence (the group for which vaccination was recommended by SAGE in 2016), over 
a 5-year follow-up from the first vaccine dose, for every 1 excess case of hospitalized dengue 
in seronegative vaccinees there would be about 7 hospitalized cases prevented in seropositive 
vaccinees, and 1 excess severe dengue in seronegative vaccinees compared to about 4 severe 
cases prevented in seropositive vaccinees.  The benefit-risk ratio is higher in areas with higher 
seroprevalence. For example, in areas with 80% dengue seroprevalence, , for every 1 excess 
case within a 5- year period of hospitalized dengue in seronegative vaccinees there would be 
about 13 cases prevented in seropositive vaccinees, and for every 1 excess case of severe 
dengue in seronegative vaccinees there would be about 7 severe cases prevented in 
seropositive vaccinees. From a population perspective, if 1,000,000 children were vaccinated 
in settings of 80% seroprevalence in the vaccinated group, about 11,000 hospitalized dengue 
cases would be averted (12,000 averted in seropositive vaccinees, 1,000 excess cases in 
seronegative vaccinees) within 5 years after vaccination: about 2,800 severe dengue cases 
would be averted (3,200 averted in seropositive vaccinees, 460 excess cases in seronegative 
vaccinees) within 5 years after vaccination. Thus, in high transmission settings, the vaccine 
provides overall population benefit, but excess cases of severe dengue will occur in 
seronegative individuals.  
  
Considerations with regards to two potential use scenarios 
The SAGE WG recognized that although the risk to those dengue seronegative would be 
avoided if the vaccine was not used at all, this would deprive those who are seropositive of a 
vaccine with reasonably high efficacy. In high prevalence settings, this latter group would 
comprise the majority. After reviewing possible strategies to use the vaccine, the WG 
primarily considered two possible vaccination strategies.  
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Strategy 1: Mass vaccination in areas with documented seroprevalence rates above 80%. The 
rationale for this strategy is that vaccination based on high seroprevalence criteria would 
result in a substantially larger number of severe and hospitalized dengue cases prevented in 
vaccinated seropositive individuals than the number of excess cases as a result of vaccinating  
seronegative individuals.  
Strategy 2: Pre-vaccination screening. The rationale for this strategy is that screening and 
vaccinating only those tested seropositive retains the benefits of vaccination seropositive 
individuals while eliminating, or greatly reducing, the risks to seronegative individuals 
(depending on the specificity of the screening test).  
 
In the discussion of these two strategies, the WG addressed various questions: What are the 
ethical considerations to balance population level benefit against individual risk? Which 
strategy would lead to the highest vaccine uptake? How feasible would be the implementation 
of serosurvey studies and individual pre-vaccination screening? Which strategy would be 
more acceptable by communities and ensure continued confidence in dengue vaccine 
programmes and vaccination in general?  And, what would be the communication challenges?  
 
Ethical considerations of population benefit versus individual risk 
In settings with high seroprevalence, the number of cases of hospitalised and severe dengue 
prevented in seropositive individuals is substantially greater than the number precipitated in 
seronegative individuals. A trade-off exists, therefore, between the population benefit 
conferred by vaccination, and the enhanced risk to the subset of seronegative vaccine 
recipients. In high transmission settings, the great majority of people have at least two natural 
dengue infections in their lifetime and thus experience the enhanced risk of more severe 
dengue associated with the second natural infection. Thus, under the assumptions used in the 
mathematical modelling21, in seronegative individuals, vaccination brings forward the risk 
period for severe dengue but does not increase the lifetime risk of severe dengue except in 
transmission settings where not everyone is likely to experience two natural dengue infections 
in their lifetime. However, it should be emphasised that this is based on a model of vaccine 
action, which cannot be confirmed or refuted by the available trial data. Furthermore, even if 
the model is correct, bringing forward in time a potentially fatal disease has ethical 
implications. 
 
The ethical tension between personal and population benefit in vaccination programmes is not 
new. Vaccines are given to healthy individuals to prevent illness, and thus the tolerance for 
vaccine adverse events is very low. Routine vaccines, like all medical products, are associated 
with some individual risk that is usually extremely low and greatly outweighed by the 
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benefits to both individuals and communities. The relative magnitude of societal benefits and 
individual risks is an important consideration when evaluating the acceptability of added risk, 
together with other key considerations such as public acceptance. For example, it is known 
that rotavirus vaccination is associated with a very small risk of inducing intussusception, but 
this risk is greatly outweighed by the protective effective effect of the vaccine against severe 
rotavirus disease.31 However, an important difference between CYD-TDV and rotavirus 
vaccines is that in the case of the latter it is not possible to predict which vaccinated children 
will develop intussusception, but with respect to CYD-TDV, the subgroup at increased risk of 
severe dengue, namely the seronegative individuals, are technically identifiable.  The ethical 
duty to “do no harm” might, arguably, thus require identifying such individuals and 
withholding vaccination from them.  
 
Testing and vaccinating only seropositive individuals is also not without ethical tensions. This 
strategy would avoid risk of harm to seronegative individuals and promote population health. 
However, challenges associated with developing a cost-effective, sensitive and specific rapid 
test may mean that the vaccine cannot be used in large-scale vaccination programmes for 
several years. Thus, there would be a cost in terms of forgone benefits for seropositive 
individuals, and population health more generally, in high transmission settings, if 
vaccination was delayed. Furthermore, unless the test had 100% specificity some truly 
seronegative individuals might be incorrectly vaccinated, and still be placed at enhanced risk 
 
Some ethicists have drawn a distinction between harms resulting from acts, such as the harms 
resulting from vaccinating someone (i.e. the harms to seronegatives vaccinees), and those 
resulting from omission, such as the harms resulting from not vaccinating someone (i.e. the 
harms to those seropositive by not offering a vaccine with proven efficacy). The “trolleyology” 
analogy, in the accompanying editorial to the publication of the new analyses from the trials, 
aptly portrays this dilemma.32 Though the goal to prevent significant harm that might result 
from omission sometimes justifies actively causing smaller harms33, there is no consensus on 
how trade-offs should be made between the two kinds of harm (i.e. how many cases must be 
prevented for every case induced). Thus, the choice of the appropriate strategy for the public 
health use of CYD-TDV should also depend on acceptability to communities, what is feasible 
for vaccination programmes, and cost-effectiveness. 
 
Implementation issues 
If strategy 1 were to be adopted, first a population serosurvey would be undertaken to identify 
population groups among whom seroprevalence levels are high enough to ensure substantial 
public health impact, followed by implementation of mass vaccination in those groups. Given 
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the now proven harm in seronegative individuals, opting for seroprevalence thresholds higher 
than 70% would be warranted, which makes the seroprevalence criteria harder to implement. 
For example, opting for seroprevalence thresholds above 80% at the age of 9 years is 
associated with several implementation challenges. Dengue transmission maps estimate that 
not many subnational areas at administrative level 1, even in high dengue endemic countries, 
have areas with seroprevalence above 80% at age 9 years.34 Very few locations have 
seroprevalence > 80% in 9 year olds, and even fewer have locations with seroprevalence 
>90% in 9 year olds. In the trial sites for Phase 3 efficacy studies, selected for their high 
dengue incidence, the seroprevalence rates for the age group 9-12 years were 75.7% in the 
Asian trial and 76.4% in the Latin American trial.35 Furthermore, there is evidence of high 
spatial and temporal heterogeneity of dengue transmission, even in small geographic 
areas.36,37 The spatiotemporal heterogeneity of dengue transmission combined with the need 
for high seroprevalence thresholds would necessitate multiple serosurveys to identify suitable 
areas at micro scale, possibly down to district or sub-district level, thus adding complexity 
and cost to any public vaccination programme. WHO`s guidance on designing and 
implementing cross-sectional serosurveys to estimate age-specific dengue seroprevalence 
highlights that such seroprevalence studies will require considerable resources and 
expertise.38 Lastly, given the limited administrative level 1 areas with seroprevalence rates 
above 80% at the age of 9 years, national vaccine coverage rates could be low and hence the 
overall public health impact would be relatively small.  
An advantage of pre-vaccination screening strategy over mass vaccination based on 
population seroprevalence criteria is that screening may be considered in moderate 
transmission settings. As individuals who have had only one dengue infection would be the 
target group that will benefit most from CYD-TDV, the optimal age for vaccine introduction 
will depend on dengue transmission intensity and can be informed by country specific data on 
the age at which hospitalizations attributed to dengue peak.14 
 
Despite the advantages of pre-vaccination screening, major challenges still need to be 
addressed. Although dengue IgG ELISA are readily available in most dengue endemic 
countries, they do not provide instant information on an individual’s serostatus, which would 
hamper vaccination campaigns.39 For large-scale vaccination programmes, screening tests 
would need to be deliverable at point-of-care as rapid diagnostic tests (RDTs). However, to 
date, no RDTs have been validated and licensed for the indication of screening for past 
dengue infection. Screening tests would need to be highly specific to avoid vaccinating truly 
seronegative persons and would need to have high sensitivity to ensure that a high proportion 
of seropositive persons are vaccinated. However, specificity is unlikely to be 100% due to 
  
12 
12 
cross-reactivity with other flaviviruses, and flavivirus vaccines.39 The acceptability of the 
level of specificity may also differ dependent upon seroprevalence settings.  Using a 
screening test with 80% specificity for a pre-vaccination screening strategy, 4% of the 
population in a seroprevalence setting of 80% would incorrectly be classified as seropositive 
and be at a potential increased risk of severe disease.  Using a screening test with 98% 
specificity would result in 0.4% of the population at such risk. In lower transmission settings, 
a test with very high specificity would be required to ensure that the risk of inadvertently 
vaccinating seronegative individuals was low. The pre-test probability of an individual being 
seropositive would be higher in settings with high endemic transmission and thus a screening 
strategy would likely be more cost-effective in such settings. Furthermore, pre-vaccination 
screening may pose significant logistic hurdles in large-scale vaccination programmes, 
including costs (of the test per se and logistics of testing)40, the need to take a blood sample 
prior to vaccination, and community acceptance of such a vaccination strategy. 
 
Communication and public confidence in vaccine programmes 
A mass vaccination strategy, based on a seroprevalence threshold, may affect public 
confidence in national vaccination programmes. Communication would have to ensure full 
disclosure of potential risks and benefits of vaccinating persons of unknown serostatus. The 
inability of vaccinees to know their own serostatus may lead to increased vaccine hesitancy. 
As the at-risk subpopulation is technically identifiable, public acceptance of a potentially 
avoidable risk may be low. Although in a mass vaccination programme in areas of high 
seroprevalence, most vaccinated individuals may ultimately benefit from the vaccination 
based on the mathematical modelling, nevertheless, some cases of severe dengue will occur 
(either in seropositive individuals as the vaccine is not completely efficacious, or in those 
seronegatives primed by the vaccine) thus potentially damaging the reputation of the vaccine 
programme, which may also have adverse consequences on public acceptance of other 
vaccines. Local, recent, age-stratified seroprevalence studies would have to be used to guide 
decision-making and introduction at subnational levels; and introducing mass vaccination 
programmes in some settings but not others (because not all areas would qualify) would result 
in complex communication issues to the public.  
 
With a pre-vaccination screening strategy, the communication to the public regarding the 
rationale for pre-vaccination screening, including blood taking, would also be complex. That 
vaccination is only appropriate for those with a past dengue infection may be counterintuitive 
to the lay public, given their experience with other vaccines, and could also lead to confusion 
amongst health care providers. Furthermore, some truly seronegative individuals will be 
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unintentionally vaccinated if the screening test is less than 100% specific. In addition, 
although the efficacy against dengue infections in seropositive individuals is high, it is still 
not complete. Therefore, transparent communication is needed to inform vaccinees that they 
are still at risk of dengue and should adhere to other disease preventive measures.  
 
Conclusions and SAGE recommendations April 2018 
The WG concluded that both “mass vaccination based on population seroprevalence criteria” 
and “pre-vaccination screening” are difficult to implement in vaccination programmes and 
neither may achieve high population protection from dengue. The WG summarized the 
advantages and disadvantages of each strategy (Table 1). It was the combination of 
implementation issues, vaccine coverage achieved, ethical and communication considerations 
that led the WG to clearly favour the pre-vaccination screening strategy over the 
seroprevalence threshold mass vaccination strategy. The proposed recommendations from the 
WG on the public health use of CYD-TDV were presented to, and adopted by, SAGE on 18 
April 2018 as follows: “For countries considering CYD-TDV vaccination as part of their 
dengue control programme, a pre-vaccination screening strategy, in which only dengue-
seropositive persons are vaccinated, is the preferred strategy. Vaccination should be 
considered as part of an integrated dengue prevention and control strategy together with well-
executed and sustained vector control and the best evidence-based clinical care.”41 
 
Important research and implementation questions remain for CYD-TDV, in particular the 
urgent development of validated sensitive and specific RDTs to determine serostatus, 
simplified immunization schedules, and assessment of the need for a booster dose. 
Furthermore, locally applicable cost-effectiveness studies are essential to underpin policy 
decisions to introduce the vaccine. Cost-effectiveness studies would need to consider the local 
epidemiology, hospitalization rates due to dengue and associated health care costs, the cost of 
the vaccine and the cost of pre-vaccination screening (programmatic issues and the costs of 
the RDTs per se). Lastly, implementation strategies need to be tested to evaluate how best to 
roll out nationally acceptable “test and vaccinate” approaches.  
 
Based on the SAGE recommendations, WHO is developing a revised dengue vaccine position 
paper that will be released in the Weekly Epidemiological Record on 7 September 2018.  This 
recommendation will be specific to CYD-TDV, and will be revised when further dengue 
vaccines42,43, currently in late stage clinical development, become available.  
 
Many lessons can be learned from the CYD-TDV experience, including the need for assays 
that can differentiate between type-specific immune response to dengue viruses versus cross-
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reactive responses to determine whether the vaccine is likely to offer protection against all 4 
dengue viruses.44 Immune correlates for both risk and protection are urgently needed.45 Given 
the now strong evidence for the major impact of serostatus on the performance of CYD-TDV, 
WHO guidance specifies that, for trials of new dengue vaccines, not only should there be 
long-term follow-up those vaccinated, but blood samples should be taken from all trial 
participants prior to vaccination, and analysis plans should include stratification of results by 
serostatus.46  
 
A dengue vaccine remains a public health priority, and all efforts should be taken to ensure 
the best use of the currently available dengue vaccine, and development of second-generation 
dengue vaccines.  
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Table 1. Comparison of the two strategies: population seroprevalence criteria versus 
individual pre-vaccination screening 
 Population Seroprevalence Criteria  
without Screening 
Pre-Vaccination Screening 
Benefits and harm Overall substantial population benefit in areas 
with high transmission predicted. 
 
 
An identifiable subset of the population will be 
put at increased risk of severe dengue, at least in 
the short to medium term. 
Maximizing the benefit (high efficacy and good 
safety) in seropositive individuals while avoiding 
harm in correctly identified those seronegative.  
 
Some seronegative individuals will be put at 
increased risk of severe dengue if vaccinated due 
to a false positive screening test result.  
Proportion of 
vaccinated population 
that will be put at 
increased risk of severe 
dengue 
Dependent on seroprevalence criteria chosen: if 
vaccine is introduced in a setting with 80% 
seroprevalence, 20% of the vaccinated 
population will be put at risk.  
Dependent on the specificity of the screening 
test. 
 
In a setting with 80% seroprevalence and a test 
with 80% specificity, 20% of true seronegatives 
will be unintentionally vaccinated. That is, 4% of 
the total population would be unintentionally 
vaccinated. 
In a setting with 80% seroprevalence and a test 
with 98% specificity, 0.4% of the population 
would be unintentionally vaccinated. 
 
The requirements for specificity depends on 
background seroprevalence. In a setting with 
lower seroprevalence, the test specificity will 
need to be higher; in a setting with a higher 
seroprevalence, a test with lower specificity may 
be acceptable. However, the aim is to develop a 
test with a high specificity to minimize harm to 
seronegative individuals.  
Population eligible for 
vaccination 
Subnational areas with seroprevalence >80% in 9 
year olds are predicted by modelling to be rare, 
those with seroprevalence >90% by the age of 9 
years very rare. 
Coverage will be higher on a population basis 
compared to the seroprevalence criteria 
strategy, as all seropositive persons in the 
population are eligible.  
 
Strategy can be used in both high and moderate 
transmission settings, although pre-test 
probability of seropositivity will be higher in high 
transmission settings. 
Negative consequences Loss in vaccine confidence (dengue vaccines and 
possibly other vaccines). 
 
Inability of vaccinees to know own serostatus 
may lead to increased vaccine hesitancy. 
Risk of false positive test in truly seronegative 
individuals resulting in vaccination of truly 
seronegative individuals 
Challenges for 
implementation 
Dengue transmission exhibits a high 
spatiotemporal heterogeneity. To identify 
subnational areas with seroprevalence above 
80% by age 9 years, multiple small-scale age 
stratified seroprevalence studies need to be 
conducted. 
 
Limitations of available tests require additional 
validation work to estimate seroprevalence. 
 
Providing appropriate information to those 
eligible for vaccination of the potential risks and 
benefits will be more challenging than for other 
vaccines. 
Pre-vaccination blood sampling may lead to 
decreased acceptance of the vaccination 
programme  
 
No RDT has been validated or licensed for the 
indication of screening for past dengue infection. 
 
Tests with high sensitivity are needed to ensure 
that a large proportion of seropositive 
individuals will benefit from CYD-TDV. 
   
Age Seroprevalence threshold in target age group Seropositive individuals of any age as indicated 
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 Population Seroprevalence Criteria  
without Screening 
Pre-Vaccination Screening 
increases for higher target ages. So, while 80% 
seroprevalence required for a target age of 9 
years, a seroprevalence threshold of 90% or 
more is required if 16-year olds are targeted. 
 
 
in the label can be targeted.  
 
As monotypic seropositive individuals would be 
the target group that will benefit most from CYD-
TDV, the optimal age for vaccine introduction 
will depend on dengue transmission intensity 
and can be informed by the age at which dengue 
hospitalisations due to severe dengue peaks. 
Cost effectiveness Cost effectiveness studies not done for scenarios 
of >80% seroprevalence. Cost effectiveness 
studies done in 2016 for seroprevalence 
threshold at 70% can be found in21 
 
Cost-effectiveness studies need to consider the 
costs required to conduct population 
serosurveys to identify sub-national areas with 
seroprevalence above 80%. 
No cost-effectiveness studies have been 
conducted to date. 
 
 
 
Cost-effectiveness studies need to take into 
account costs associated with identifying 
seropositives. 
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